The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing
Open accessAbstract
Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo-controlled studies failed to find compelling evidence for this. The present study collected web-based mental health and related data using a prospective (before, during and after) design. Individuals planning a weekly microdosing regimen completed surveys at strategic timepoints, spanning a core four-week test period. Eighty-one participants completed the primary study endpoint. Results revealed increased self-reported psychological well-being, emotional stability and reductions in state anxiety and depressive symptoms at the four-week primary endpoint, plus increases in psychological resilience, social connectedness, agreeableness, nature relatedness and aspects of psychological flexibility. However, positive expectancy scores at baseline predicted subsequent improvements in well-being, suggestive of a significant placebo response. This study highlights a role for positive expectancy in predicting positive outcomes following psychedelic microdosing and cautions against zealous inferences on its putative therapeutic value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Agreeableness and openness to experience did not change at all after MD compared to baseline in the current study, contrasting results from earlier MD studies (12, 28).”
From Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Agreeableness was increased after MD in a general population sample (12)”
From Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“but other studies did not find this effect in a general population sample (12) and a general sample without individuals diagnosed with a mood, anxiety, substance use, psychotic or dissociative disorder (13).”
From Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Neuroticism decreased after MD in healthy adults (29) and a general population sample (12)”
From Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“The decrease in neuroticism reported here is consistent with two previous prospective MD studies (12, 29).”
From Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Kaertner et al. (2021) found that positive expectancy scores regarding the effects of microdosing at baseline predicted subsequent improvements in wellbeing.”
From Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study (2023) · cites this paper as Kaertner et al. (2021)
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A very brief measure of the Big-Five personality domains
Gosling, S. D., Rentfrow, P. J., & Swann, W. B. (2003) · Journal of Research in Personality · doi:10.1016/s0092-6566(03)00046-1 · Cited by 8,307
The brief resilience scale: Assessing the ability to bounce back
Smith, B. W., Dalen, J., Wiggins, K., Tooley, E., Christopher, P., & Bernard, J. (2008) · International Journal of Behavioral Medicine · doi:10.1080/10705500802222972 · Cited by 6,439
The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation
Tennant, R., Hiller, L., Fishwick, R., Platt, S., Joseph, S., Weich, S., Parkinson, J., Secker, J., & Stewart-Brown, S. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-63 · Cited by 5,031
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Marteau, T. M., & Bekker, H. (1992) · British Journal of Clinical Psychology · doi:10.1111/j.2044-8260.1992.tb00997.x · Cited by 3,238
Psychometric properties of the credibility/expectancy questionnaire
Devilly, G. J., & Borkovec, T. D. (2000) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/s0005-7916(00)00012-4 · Cited by 2,295
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Tellegen, A., & Atkinson, G. (1974) · Journal of Abnormal Psychology · doi:10.1037/h0036681 · Cited by 2,196
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Measuring belongingness: The Social Connectedness and the Social Assurance scales.
Lee, R. M., & Robbins, S. B. (1995) · Journal of Counseling Psychology · doi:10.1037/0022-0167.42.2.232 · Cited by 1,484
The Five-Factor Model of Personality and Its Relevance to Personality Disorders
Costa, P. T., & McCrae, R. R. (1992) · Journal of Personality Disorders · doi:10.1521/pedi.1992.6.4.343 · Cited by 1,472
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
The neuroscience of placebo effects: connecting context, learning and health
Wager, T. D., & Atlas, L. Y. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3976 · Cited by 844
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
The NR-6: a new brief measure of nature relatedness
Nisbet, E. K., & Zelenski, J. M. (2013) · Frontiers in Psychology · doi:10.3389/fpsyg.2013.00813 · Cited by 731
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683
Psychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657
Sota, J., Insalaco, A., Cimaz, R., Alessio, M., Cattalini, M., Gallizzi, R., Maggio, M. C., Lopalco, G., Torre, F. L., Fabiani, C., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01526 · Cited by 616
Measuring Delusional Ideation: The 21-Item Peters et al. Delusions Inventory (PDI)
Peters, E., Joseph, S., Day, S., & Garety, P. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007116 · Cited by 607
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662634 · Cited by 596
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587
Self-citationThe therapeutic role of 5-HT1A and 5-HT2A receptors in depression
Celada, P., Puig, M. V., Amargós‐Bosch, M., Adell, A., & Artigas, F. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0427 · Cited by 525
Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517
Variability in sea ice cover and climate elicit sex specific responses in an Antarctic predator
Labrousse, S., Sallée, J., Fraser, A. D., Massom, R. A., Reid, P., Hobbs, W. R., Guinet, C., Harcourt, R. G., McMahon, C. R., Authier, M., et al. (2017) · Scientific Reports · doi:10.1038/srep43236 · Cited by 508
Constructing drug effects: a history of set and setting
Hartogsohn, I. (2017) · Drug Science Policy and Law · doi:10.1177/2050324516683325 · Cited by 472
Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI).
Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00269 · Cited by 470
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455
The brief experiential avoidance questionnaire: Development and initial validation
Gámez, W., Chmielewski, M., Kotov, R., Ruggero, C., Suzuki, N., & Watson, D. (2014) · Psychological Assessment · doi:10.1037/a0034473 · Cited by 450
Predicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417
Active placebos versus antidepressants for depression
Moncrieff, J., Wessely, S., & Hardy, R. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003012.pub2 · Cited by 342
LSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320
Self-citationPetrie, K. J., & Rief, W. (2019) · Annual Review of Psychology · doi:10.1146/annurev-psych-010418-102907 · Cited by 309
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293
Modern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236
A systematic study of microdosing psychedelics
Polito, V., & Stevenson, R. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211023 · Cited by 235
Hartogsohn, I. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00129 · Cited by 229
Kuypers, K. P. C., Ng, L., Erritzøe, D., Knudsen, G. M., Nichols, C. D., Nichols, D. E., Pani, L., Soula, A., & Nutt, D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119857204 · Cited by 227
The nocebo effect: patient expectations and medication side effects
Faasse, K., & Petrie, K. J. (2013) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2012-131730 · Cited by 201
Bershad, A. K., Schepers, S. T., Bremmer, M. P., Lee, R., & de Wit, H. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.019 · Cited by 179
Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting
Prochazkova, L., Lippelt, D. P., Colzato, L. S., Kuchar, M., Sjoerds, Z., & Hommel, B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5049-7 · Cited by 177
Yanakieva, S., Polychroni, N., Family, N., Williams, L. T. J., Luke, D. P., & Terhune, D. B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5119-x · Cited by 174
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., Hapke, E., & Farb, N. A. S. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5106-2 · Cited by 174
Cameron, L. P., Benson, C. J., DeFelice, B. C., Fiehn, O., & Olson, D. E. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00692 · Cited by 168
Byock, I. (2018) · Journal of Palliative Medicine · doi:10.1089/jpm.2017.0684 · Cited by 161
Powerful substances in tiny amounts: An interview study of psychedelic microdosing
Johnstad, P. G. (2018) · Nordic Studies on Alcohol and Drugs · doi:10.1177/1455072517753339 · Cited by 155
Family, N., Maillet, É. L., Williams, L. T. J., Krediet, E., Carhart-Harris, R. L., Williams, T. A., Nichols, C. D., Goble, D. J., & Raz, S. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05417-7 · Cited by 145
The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys
Fadiman, J. (2011) · Cited by 138
Psychedelic microdosing benefits and challenges: an empirical codebook
Anderson, T., Petranker, R., Christopher, A., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., & Hapke, E. (2019) · Harm Reduction Journal · doi:10.1186/s12954-019-0308-4 · Cited by 133
Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Varghese, N., Eckert, A., Feilding, A., Ramaekers, J. G., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00099 · Cited by 131
Motives and Side-Effects of Microdosing With Psychedelics Among Users
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., & Kuypers, K. P. C. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz029 · Cited by 126
Active placebos versus antidepressants for depression (Review)
Moncrieff, J., Wessely, S. C., & Hardy, R. (2004) · UCL Discovery (University College London) · Cited by 125
Psychedelic Microdosing: Prevalence and Subjective Effects
Cameron, L. P., Nazarian, A., & Olson, D. E. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1718250 · Cited by 110
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers
Ramaekers, J. G., Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Feilding, A., & Kuypers, K. P. C. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120940937 · Cited by 97
Day-To-Day Affect is Surprisingly Stable
Hudson, N. W., Lucas, R. E., & Donnellan, M. B. (2016) · Social Psychological and Personality Science · doi:10.1177/1948550616662129 · Cited by 79
Eklund, A., De Carvalho, D., Pagé, I., Wong, A., Johansson, M. S., Pohlman, K. A., Hartvigsen, J., & Swain, M. (2019) · European Journal of Pain · doi:10.1002/ejp.1407 · Cited by 76
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities
Rosenbaum, D., Weissman, C., Anderson, T., Petranker, R., Dinh-Williams, L.-A., Hui, K., & Hapke, E. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120908004 · Cited by 76
Κube, T., & Rief, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.022 · Cited by 59
Bjørkedal, E., & Flaten, M. A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2233-4 · Cited by 54
Berna, C., Kirsch, I., Zion, S. R., Lee, Y., Jensen, K. B., Sadler, P., Kaptchuk, T. J., & Edwards, R. R. (2017) · Pain · doi:10.1097/j.pain.0000000000000870 · Cited by 54
Spriggs, M. J., Sumner, R. L., McMillan, R. L., Moran, R., Kirk, I. J., & Muthukumaraswamy, S. D. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.04.060 · Cited by 38
The Psychedelic Explorer’s Guide: Safe, Therapeutic, and Sacred Journeys
Rhead, J. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.948329 · Cited by 30
SUBJECT EXPECTANCY AND ENVIRONMENTAL FACTORS AS DETERMINANTS OF PSYCHEDELIC FLASHBACK EXPERIENCES
Heaton, R. K. (1975) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-197509000-00002 · Cited by 19
Placebo and its evil twin, nocebo
Glick, M. (2016) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2016.02.009 · Cited by 16
Deschepper, R., Six, S., Vandeweghe, N., Couck, M., Gidron, Y., Depoorter, A., & Bilsen, J. J. R. (2017) · Methodological Innovations · doi:10.1177/2059799117703119 · Cited by 9
Villani, D., Iannello, P., Cipresso, P., & Antonietti, A. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2017.02092 · Cited by 6
Cited by
Sorted by citations
Blinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
de la Fuente Revenga, M., Zhu, B., Guevara, C. A., Naler, L. B., Saunders, J. M., Zhou, Z., Toneatti, R., Sierra, S., Wolstenholme, J. T., Beardsley, P. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109836 · Cited by 224
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
Cavanna, F., Muller, S. L., de la Fuente, L. A., Zamberlán, F., Palmucci, M., Janeckova, L., Kuchař, M., Pallavicini, C., & Tagliazucchi, E. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02039-0 · Cited by 157
Therapeutic effect of psilocybin in addiction: A systematic review
van der Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., de Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bossong, M. G., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1134454 · Cited by 127
Metadata
- Authors
- Kaertner, L. S., Steinborn, M. B., Kettner, H., Spriggs, M. J., Roseman, L., Buchborn, T., Balaet, M., Timmermann, C., Erritzoe, D., & Carhart-Harris, R. L.
- Affiliations
- University of Würzburg (DE)
- Imperial College London (GB)
- ORCID
- Venue
- Scientific Reports
- Published
- 2021-01-21
- Volume
- 11
- Issue
- 1
- Pages
- 1941-1941
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7820236
- OpenAlex
- W3122801192
- Cited by
- 145
- References
- 76
- Citations by year
- 2026: 6 · 2025: 26 · 2024: 34 · 2023: 37 · 2022: 24 · 2021: 18
- FWCI
- 19.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion, cc-by)
- Funders
- National Institute for Health and Care Research (ACF-2013-21-501, CL-2017-21-004)
- Academy of Medical Sciences (SGL019\1063)
- Imperial College London
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Psychology › Social Psychology › Psychological Well-being and Life Satisfaction
- Keywords
- psychedelic microdosing, positive expectations, placebo response, psychological well-being, state anxiety, depressive symptoms, emotional stability, psychological resilience, social connectedness, agreeableness, nature relatedness, psychological flexibility, classic psychedelics
- MeSH terms
- Adult, Affect, Anxiety, Dose-Response Relationship, Drug, Emotions, Female, Hallucinogens, Humans, Lysergic Acid Diethylamide, Male, Mental Health, Middle Aged, Motivation, Psilocybin, Quality of Life, Placebo Effect, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review